The ‘Quest’ for an Effective Partner in Pharma and Biotech
David Freeman, General Manager, Information Ventures, for Quest Diagnostics, discusses how his company can be an effective partner for pharma and biotech firms.
Operational Complexity in Cell and Gene Therapy Trials
As advanced therapy technology and manufacturing evolve, there are three key operational challenges to address unique to these products.
Alzheimer’s Research Finds New Beginnings
Despite mounting frustrations in drug R&D for Alzheimer's disease, emerging biopharma firms are still pursuing AD therapies with new science, and different preclinical and clinical trial models.
Eliminating ‘Disruption’ for Patients in Clinical Trials
Exploring new ways to smooth the path toward better participation for patients and other research and healthcare stakeholders.
Data Manipulation Case Spotlights Wider Concerns, Actions
Regulatory enforcement actions, policy updates, and new guidelines show that ensuring the reliability of clinical data is an ongoing priority.
Applied Clinical Trials, October 2019 Issue (PDF)
Click the title above to open the Applied Clinical Trials October 2019 issue in an interactive PDF format.
Patient Experience Comes to Drug Development
The transformation in patient perceptions will only happen when the five million Americans who’ve already participated in clinical trials can directly share their experiences with the next five million people considering participating.
Industry Report on Outsourcing Spend, Models, and Measures
A look at the findings from Avoca Group’s 2018 industry research survey on clinical outsourcing.
Fighting High Prices for Innovative Drugs with NHS Generic Production
A strongly-worded plan for reining-in profit-driven drug firms receives immediate backlash as arguments over drug pricing and patient access continue to rage around Europe and the US.
Hospital Angelina Caron Joins Clinerion’s Patient Network
SCRS Announces Partnership with TrialScout
Addressing the Unique Needs of Emerging Biopharma in Drug Development
CEO of Synteract, Steve Powell, discusses the advantages that mid-sized CROs-like his own-offer emerging drug developers to navigate continually changing processes.
Veeva to Acquire Crossix
Fighting High Prices for Innovative Drugs with State-Owned Generic Production
SCDM Releases Trends Impacting Clinical Data Management
Overcoming the Complexities of Neurodegenerative Clinical Trials
COO and CMO of BrainStorm, Ralph Kern, discusses how his company is overcoming challenges and advancing science in neurodegenerative disease.
Medrio and Bioforum Partner
Andaman7 and O.I.s Announce Partnership
TrialAssure Releases ANONYMIZE DS
PPD Expands Bioanalytical Laboratory Capabilities
QPS Expands with Three New Facilities
